New research, involving 200 professionals in senior roles spanning pharmacovigilance (PV), Drug Safety and Product Safety departments, has found that quality has overtaken cost as a priority in plans for automating adverse event (AE) reporting. John Price, life sciences industry consultant and partner of Arriello, which commissioned this latest research, reports on the findings.  Although the Covid-19 pandemic has stalled progress with digital process […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!